Your browser doesn't support javascript.
loading
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
Struble, Kimberly; Chan-Tack, Kirk; Qi, Karen; Naeger, Lisa K; Birnkrant, Debra.
Affiliation
  • Struble K; Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
  • Chan-Tack K; Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
  • Qi K; Office of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
  • Naeger LK; Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
  • Birnkrant D; Division of Antiviral Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
Hepatology ; 67(2): 482-491, 2018 02.
Article in En | MEDLINE | ID: mdl-29059462
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Hepatitis C, Chronic Type of study: Etiology_studies / Risk_factors_studies Limits: Adult / Humans Country/Region as subject: America do norte Language: En Journal: Hepatology Year: 2018 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Hepatitis C, Chronic Type of study: Etiology_studies / Risk_factors_studies Limits: Adult / Humans Country/Region as subject: America do norte Language: En Journal: Hepatology Year: 2018 Document type: Article Affiliation country: Country of publication: